AC
ALBO

Apogem Capital’s Albireo Pharma Inc ALBO Stock Holding History

Apogem Capital’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,600
Closed -$91K – 214
2021
Q2 		$91K Buy
+2,600
New +$84.5K 0.06% 181

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Apogem Capital's ALBO Position: Q4 2022 in Review

Apogem Capital sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 34,524 shares — an estimated $668K sold.

Apogem Capital first reported a position in ALBO in Q4 2020 and held it in 8 quarters. The position peaked at $1.07M in Q3 2021. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Apogem Capital reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 34,524 Albireo Pharma Inc shares in Q4 2022, an estimated $668K.
  • Apogem Capital first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 8 quarters.
  • Apogem Capital's Albireo Pharma Inc position peaked at $1.07M in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.